Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report.
bevacizumab
case report
irinotecan
low-grade gliomas
pilocytic astrocytoma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
22
06
2023
accepted:
14
08
2023
medline:
6
10
2023
pubmed:
6
10
2023
entrez:
6
10
2023
Statut:
epublish
Résumé
Low grade gliomas (LGGs) of pineal region are usually difficult to remove and they frequently relapse or progress after front line chemotherapy. Bevacizumab-Irinotecan (BEVIRI) combination has been successfully attempted in children with recurrent LGGs, in most cases not previously irradiated. The efficacy of bevacizumab has also been described in radiation necrosis. Considering the possible overlapping of radiation treatment effect and disease progression and difficulty in differentiating, we report on the use of BEVIRI in a case of a recurrent relapsing low-grade glioma of the pineal region, subjected to multiple neurosurgical interventions, also treated with a carboplatin-etoposide regimen and a radiation course, at present at one-year follow-up showing a stable response, with no adverse events.
Identifiants
pubmed: 37799478
doi: 10.3389/fonc.2023.1244628
pmc: PMC10547897
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1244628Informations de copyright
Copyright © 2023 Castelli, Fonte, Guidi, Tellini, Di Nicola, Iacono, Buccoliero, Greto, Genitori and Sardi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1487-95
pubmed: 20399573
Pediatr Blood Cancer. 2015 Feb;62(2):240-245
pubmed: 25382690
J Neurooncol. 2022 Apr;157(2):355-364
pubmed: 35239111
J Pediatr Hematol Oncol. 2015 Aug;37(6):e341-6
pubmed: 26056795
Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):323-6
pubmed: 17236958
Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1148-54
pubmed: 19857784
Pediatr Blood Cancer. 2018 Sep;65(9):e27234
pubmed: 29750399
Neurooncol Pract. 2020 Jul;7(4):359-368
pubmed: 33282324
J Neurooncol. 2011 May;102(3):471-5
pubmed: 20694573
Brain Tumor Res Treat. 2022 Oct;10(4):221-225
pubmed: 36347636
J Clin Oncol. 2011 Mar 1;29(7):e159-62
pubmed: 21149667
J Adv Pract Oncol. 2012 Jan;3(1):11-21
pubmed: 25031923
Mol Cancer. 2019 Feb 7;18(1):21
pubmed: 30732625
Future Oncol. 2014 May;10(7):1277-97
pubmed: 24947265
Pediatr Blood Cancer. 2009 Jul;52(7):791-5
pubmed: 19165892
Oncologist. 2015 Jul;20(7):806-11
pubmed: 26032137
J Neurooncol. 2010 Oct;100(1):65-71
pubmed: 20151174